Khardin is a bioactive compound. References: Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Nov 24;375(21):2102. doi: 10.1056/NEJMc1610828. PubMed PMID: 27959738.

纯度：≥98%

CAS：112143-77-8